These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 1387417)

  • 21. Antiviral effects of phosphonoformate (PFA, foscarnet sodium).
    Oberg B
    Pharmacol Ther; 1989; 40(2):213-85. PubMed ID: 2543994
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo additive antiretroviral effect of combined zidovudine and foscarnet therapy for human immunodeficiency virus infection (ACTG Protocol 053).
    Jacobsen MA; van der Horst C; Causey DM; Dehlinger M; Hafner R; Mills J
    J Infect Dis; 1991 Jun; 163(6):1219-22. PubMed ID: 1828075
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Foscarnet therapy in persons with AIDS: clinical research and management considerations. Introduction.
    Gazzard BG
    J Acquir Immune Defic Syndr (1988); 1992; 5 Suppl 1():S1-2. PubMed ID: 1534838
    [No Abstract]   [Full Text] [Related]  

  • 24. Foscarnet effective in acyclovir-resistant herpes.
    Am Pharm; 1991 Nov; NS31(11):12. PubMed ID: 1836936
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment of CMV retinitis.
    Skolnik PR
    N Engl J Med; 1992 Jun; 326(25):1701; author reply 1702-3. PubMed ID: 1317010
    [No Abstract]   [Full Text] [Related]  

  • 26. Problems in the management of cytomegalovirus infection in patients with AIDS.
    Connolly GM; Nelson MR; Barton SE; Gazzard BG
    Int J STD AIDS; 1991; 2(6):405-10. PubMed ID: 1664242
    [No Abstract]   [Full Text] [Related]  

  • 27. Generalised cutaneous rash associated with foscarnet usage in AIDS.
    Green ST; Nathwani D; Goldberg DJ; Mack DJ; Kennedy DH
    J Infect; 1990 Sep; 21(2):227-8. PubMed ID: 2146323
    [No Abstract]   [Full Text] [Related]  

  • 28. Liposomal encapsulation of foscarnet protects against hypocalcemia induced by free foscarnet.
    Omar RF; Dusserre N; Désormeaux A; Poulin L; Tremblay M; Beauchamp D; Bergeron MG
    Antimicrob Agents Chemother; 1995 Sep; 39(9):1973-8. PubMed ID: 8540701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Regressive diffuse leukoencephalitis under foscarnet in an AIDS infected patient].
    Nicoli F; Dhiver C; Chave B; Poizot-Martin I; Gastaut JA; Gastaut JL
    Presse Med; 1992 Mar; 21(9):436. PubMed ID: 1314379
    [No Abstract]   [Full Text] [Related]  

  • 30. Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen-comparative trial.
    Hardy WD
    Am J Med; 1992 Feb; 92(2A):30S-35S. PubMed ID: 1531285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Didanosine and foscarnet marketed for use by patients with AIDS.
    Clin Pharm; 1992 Jan; 11(1):4, 6. PubMed ID: 1309689
    [No Abstract]   [Full Text] [Related]  

  • 32. Antiviral effects of phosphonoformate (PFA, foscarnet sodium).
    Oberg B
    Pharmacol Ther; 1982; 19(3):387-415. PubMed ID: 6201932
    [No Abstract]   [Full Text] [Related]  

  • 33. Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis.
    Chrisp P; Clissold SP
    Drugs; 1991 Jan; 41(1):104-29. PubMed ID: 1706982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Foscarnet infusion at home.
    Wood G; Whitby M; Hogan P; Frazer I
    Lancet; 1989 Jan; 1(8630):156. PubMed ID: 2563066
    [No Abstract]   [Full Text] [Related]  

  • 35. The effect of increasing gastric pH upon the bioavailability of orally-administered foscarnet.
    Barditch-Crovo PA; Petty BG; Gambertoglio J; Nerhood LJ; Kuwahara S; Hafner R; Lietman PS; Kornhauser DM
    Antiviral Res; 1998 Jun; 38(3):209-12. PubMed ID: 9754889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of foscarnet (phosphonoformate) on human immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients.
    Gaub J; Pedersen C; Poulsen AG; Mathiesen LR; Ulrich K; Lindhardt BO; Faber V; Gerstoft J; Hofmann B; Lernestedt JO
    AIDS; 1987 May; 1(1):27-33. PubMed ID: 2962590
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group.
    Safrin S; Crumpacker C; Chatis P; Davis R; Hafner R; Rush J; Kessler HA; Landry B; Mills J
    N Engl J Med; 1991 Aug; 325(8):551-5. PubMed ID: 1649971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet.
    Jacobson MA; O'Donnell JJ
    J Acquir Immune Defic Syndr (1988); 1991; 4 Suppl 1():S11-5. PubMed ID: 1848616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of cytomegalovirus pneumonitis with foscarnet (trisodium phosphonoformate) in patients with AIDS.
    Farthing C; Anderson MG; Ellis ME; Gazzard BG; Chanas AC
    J Med Virol; 1987 Jun; 22(2):157-62. PubMed ID: 3039052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Foscarnet induction therapy for cytomegalovirus retinitis in AIDS: comparison of twice-daily and three-times-daily regimens.
    Katlama C; Dohin E; Caumes E; Cochereau-Massin I; Brancon C; Robinet M; Rogeaux O; Dahan R; Gentilini M
    J Acquir Immune Defic Syndr (1988); 1992; 5 Suppl 1():S18-24. PubMed ID: 1318363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.